FDA plans July public meeting on REMS submissions before issuing guidance
This article was originally published in Scrip
Executive Summary
The US FDA plans to hold a two-day public meeting beginning 27 July in order to obtain input on "issues and challenges" associated with the development and implementation of risk evaluation and mitigation strategies (REMS) for pharmaceutical products.